Research

Our research group operates at the intersection of synthetic organic chemistry and medicinal chemistry, with a primary emphasis on the discovery and development of innovative biologically active small molecules aimed at the treatment of infectious diseases. 

A significant focus of our research involves the design, synthesis, and biological evaluation of novel antituberculosis and antimicrobial agents. We endeavor to develop structurally diverse heterocyclic compounds and examine their structure–activity relationships to identify and optimize promising lead molecules. Particular attention is directed towards compounds that target biologically pertinent processes in Mycobacterium tuberculosis, specifically mycobacterial ATP synthase and the virulence-associated zinc metalloprotease Zmp1. 

Our research strategy integrates contemporary synthetic methodologies, heterocyclic chemistry, and medicinal chemistry optimization with biological screening conducted in collaboration with specialized partners. Promising compounds are subjected to further exploration concerning their potency, selectivity, physicochemical properties, and, where feasible, their mechanisms of action. 

While the discovery of antitubercular and antibacterial agents remains a central aspect of our research, recent investigations have expanded our activities towards additional classes of biologically relevant compounds. Notably, our recent publications reflect a growing interest in antitrypanosomal agents, particularly those effective against Trypanosoma species, as well as in heterocyclic scaffolds demonstrating broader antimicrobial and cytotoxic activities. These findings present novel opportunities for investigating the therapeutic potential of our compound libraries beyond their initially intended biological targets. 

Through this multidisciplinary approach, we aspire to translate innovative synthetic chemistry into new molecular tools and promising lead compounds for the advancement of antiinfective and other biologically active agents.